Shots:
Through preclinical collaboration and licensing agreement, Gilead has the option to license rights to develop and commercialize products for autoimmune diseases by using EVOQ’s NanoDisc technology
Under the agreement, EVOQ will receive ~$658.5M incl. upfront, option exercise, and milestone payments across all programs, as well as tiered royalties on product sales
NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens to restore immune tolerance
Ref: Businesswire | Image: Gilead
Related News:- Edwards Presents (TRISCEND) Study Results of EVOQUE Transfemoral Transcatheter Tricuspid Valve Replacement for Tricuspid Regurgitation at PCR 2022
